Trial Profile
Autophagic Modulation With Anti-Angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Hydroxychloroquine (Primary) ; Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.
- 09 May 2023 Planned End Date changed from 1 Apr 2023 to 1 Jul 2023.
- 09 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jul 2023.